Green Ribbon, a healthcare data-based fintech company, announced that it participated in CES 2026, held in Las Vegas, USA from January 6th to 9th, and unveiled 'GreenScout,' an AI-based clinical trial subject recruiting solution.
At this exhibition, Green Ribbon presented a clinical strategy combining digital healthcare, artificial intelligence (AI), and real-world data (RWD), drawing attention from global pharmaceutical companies, contract research organizations (CROs), and digital healthcare companies. In particular, the company emphasized the structural improvement potential of RWD-based pre-validation and AI pre-screening to address the recurring clinical delays in the FDA clinical approval process.
Green Ribbon is a data company that improves inefficiencies in the healthcare industry based on insurance and medical data. Using millions of real-life patient medical and insurance data, Green Ribbon provides individuals with medical and insurance benefit reimbursement services and provides companies with high-quality RWD infrastructure that can be utilized in actual clinical settings.
Green Scout, unveiled at this year's CES, is an AI-based clinical trial subject recruitment solution that leverages these data capabilities. Its unique feature is its shift from a post-clinical trial approach that addresses issues after they begin to a structure that verifies recruitment potential and the likelihood of success before the trial begins.
Key features were demonstrated on-site, including pre-analysis of the number of patients eligible for recruitment based on disease and diagnosis codes, prediction of recruitment speed reflecting the frequency of visits and treatment continuity by hospital, reduction of screening failure rate through AI suitability scoring, and a real-time recruiting dashboard, along with actual data flow.
This approach is evaluated as a way to reduce the risk of schedule delays and design changes that occur during the clinical trial process, and has received a positive response from global digital healthcare companies.
Kim Gyu-ri, CEO of Green Ribbon, explained, "The biggest cost in FDA clinical trials comes from delays rather than failures." Green Scout is a solution focused not simply on expediting clinical trials, but on designing them to avoid delays. She added, "CES 2026 served as an opportunity to recognize Korea's real-world patient RWD as a strategic asset in the global clinical trial market."
- See more related articles
You must be logged in to post a comment.